Evaluation of Metabolic Dysfunction–Associated Steatohepatitisas Risk Factor in Management of Non-diabetic Patients Presenting with Acute Ischemic Stroke
DOI:
https://doi.org/10.21649/akemu.v31i4.5899Keywords:
MASH, Ischemic Stroke, NIHSS, Modified Rankin ScoreAbstract
Background: Metabolic dysfunction–associated steatohepatitis (MASH) is linked to an increased risk of cardiovascular diseases, including acute ischemic strokes and diabetes. However, data on MASH as independent risk factor for ischemic stroke severity and functional outcomes remain limited. To evaluate whether Metabolic dysfunction–associated steatohepatitisserves as an independent risk factor and a marker of increased stroke severity at onset as well as its impact on functional recovery in non-diabetic patients.
Objective: To evaluate whether Metabolic dysfunction–associated steatohepatitisacts as an independent risk factor contributing to the severity of acute ischemic stroke at presentation and affecting functional recovery outcomes in non-diabetic patients.
Methods: This prospective observational cohort, hospital-based study was conducted at Sir Ganga Ram Hospital Lahore, enrolling 54 non-diabetic patients who consented and met inclusion criteria. Patients underwent abdominal ultrasound for MASH screening, with the FIB-4 score calculated from blood samples (age, AST, ALT, and platelet count).27 patients with MASH (GROUP A) were compared to 27 without MASH (GROUP B). The CT scan assessed ischemic stroke at admission, and NIHSS score was recorded. Follow-ups at three and six months involved repeat CT scans and Modified Rankin Score to evaluate disability.
Results: The MASH group had significantly higher mean Body Mass Index (BMI) of 38 kg/m² compared to 28.6 kg/m² in the non-MASH group (p=0.001). NIHSS scores were also higher in the MASH group (26.2 vs. 15.5, p=0.001). At three months, the Modified Rankin score averaged 3.52 in the MASH group versus 2.81 in the non-MASH group (p=0.04). Additionally, more MASH patients presented with reduced consciousness (29.6% vs. 7.4%, p=0.03).
Conclusion: this study highlights the adverse impact of MASH on ischemic stroke severity and functional outcomes in non-diabetic patients, underscoring the need for tailored management strategies.
References
1. Padda J, Khalid K, Khedr A, Tasnim F, Al-Ewaidat OA, Cooper AC, et al. Non-alcoholic fatty liver disease and its association with diabetes mellitus. Cureus. 2021;13(8):e17321. doi: 10.7759/cureus.17321
2. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (MASH): a systematic review. Hepatol. 2023;77(4):1335-47. doi: 10.1097/HEP.0000000000000004.
3. Abbas Z, Zaheer R. Non-alcoholic fatty liver disease: A real threat in Pakistan. J Pak Med Assoc. 2020;70(12B):2437-40. doi: 10.5455/JPMA.95891.
4. Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19(1):60-78. doi: 10.1038/s41575-021-00523-4
5. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors, and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-38. doi: 10.1038/s41575-020-00381-6
6. Ando Y, Jou JH. Nonalcoholic fatty liver disease and recent guideline updates. Clin Liver Dis (Hoboken). 2021;17(1):23-8. doi: 10.1002/cld.1045.
7. Piazzolla VA, Mangia A. Noninvasive diagnosis of NAFLD and MASH. Cells. 2020;9(4):1005-9. doi: 10.3390/cells9041005
8. Petzold G. Role of ultrasound methods for the assessment of NAFLD. J Clin Med. 2022;11(15):4581-89. doi: 10.3390/jcm11154581.
9. Dumitrascu DL, Neuman MG. Non-alcoholic fatty liver disease: an update on diagnosis. Clujul Med. 2018;91(2):147-50.
10. Rajati F, Rajati M, Rasulehvandi R, Kazeminia M. Prevalence of stroke in the elderly: a systematic review and meta-analysis. Interdisciplinary Neurosurgery. 2023;32:101746. doi.org/10.1016/j.inat.2023.101746
11. Xu J, Dai L, Zhang Y, Wang A, Li H, Wang Y, et al. Severity of nonalcoholic fatty liver disease and risk of future ischemic stroke events. Stroke. 2021;52(1):103-10. doi: 10.1161/STROKEAHA
12. Canillas L, Soriano-Varela A, Rodríguez-Campello A, Giralt-Steinhauer E, Cuadrado-Godia E, Broquetas T. High prevalence of non-alcoholic fatty liver disease in patients with a first episode of acute ischemic stroke. Impact on disability and death. Front Endocrinol (Lausanne). 2022; 13(1):10038-78. doi: 10.3389/fendo.2022.1003878
13. Parikh NS, VanWagner LB, Elkind MS, Gutierrez J. Association between nonalcoholic fatty liver disease with advanced fibrosis and stroke. J Neurol Sci. 2019:407:116524. doi: 10.1016/j.jns.2019.116524.
14. Mori T, Yoshioka K, Tanno Y. Non-alcoholic fatty liver disease frequency and associated factors at admission of acute stroke. Hepatol Int. 2022;16(1):81-8. doi: 10.1007/s12072-021-10253-z
15. Tang ASP, Chan KE, Quek J, Xiao J, Tay P, Teng M, et al. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. Clin Mol Hepatol. 2022;28(3):483-96.
16. Farooq A, Ahmed S, Wasay M. Acute stroke care in Pakistan. J Coll Physicians Surg Pak. 2022;32(6):695-6. doi: 10.29271/jcpsp.2022.06.695
17. Sherin A, Ul-Haq Z, Fazid S, Shah BH, Khattak MI, Nabi F. Prevalence of stroke in Pakistan: Findings from Khyber Pakhtunkhwa integrated population health survey (KP-IPHS) 2016-17. Pak J Med Sci. 2020;36(7):1435-40. doi: 10.12669/pjms.36.7.2824
18. Grotta JC, Albers GW, Broderick JP, Kasner SE, Lo EH, Sacco RL, et al. Stroke e-book: Pathophysiology, diagnosis, and management. 7th ed. Philadelphia: Elsevier Health Sciences; 2021.
19. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors, and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223-38. doi: 10.1038/s41575-020-00381-6
20. Grory, B M, Fakhri, N, Yaghi, S. Thrombotic strokes. Cerebrovascular Disorders, pp. 243-260. New York, NY: Springer US.
21. Kim SE, Min JS, Lee S, Lee DY, Choi D. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration. Scientific Reports. 2023;13(1):15461. doi.org/10.1038/s41598-023-42788-6
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Annals of King Edward Medical University
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments publications@kemu.edu.pk